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Abstract
Background: Congenital cytomegalovirus (cCMV) infection is an important illness that is a common cause of hearing
loss in newborn infants and a major cause of disability in children. For that reason, treatment of symptomatic patients
with either ganciclovir or its pro-drug valganciclovir is recommended. Treatment duration of 6 months has been
shown to be more beneficial than shorter courses; however, there is uncertainty regarding emergence of resistance
strains, secondary effects and long term sequelae.
Case presentation: Here we present a female infant with symptomatic cCMV who was treated from day 5 of life with
oral valganciclovir. In spite of close monitoring of her drug levels and increments of her treatment dose according to
weight gain, she developed ganciclovir resistance after 4 months of treatment, with increasing viraemia and petechiae.
Adherence to treatment was assessed and felt to be good. Clinically, although she had marked developmental delay,
she was making steady progress. In view of the development of resistance treatment was stopped at 5 months of age.
No secondary effects of ganciclovir were noted during the whole course.
Conclusions: There were few cases in the literature reporting resistance to ganciclovir for cCMV before the
new recommendations for a 6 months treatment course for this infection were published. As demonstrated
in our patient, surveillance with periodic viral loads and drug monitoring are vital to identify emerging
resistance and optimise antiviral dosing according to weight gain.
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Background
Congenital cytomegalovirus (cCMV) infection is an im-
portant illness that is a common cause of hearing loss in
newborn infants and a major cause of disability in chil-
dren. A recent evidence based guideline [1] recommends
the use of ganciclovir, which is given intravenously, or
its pro-drug, oral valganciclovir, in symptomatic patients.
Currently a 6 month rather than 6 week course of val-
ganciclovir is advocated as it has shown more clinical
benefits with no increase in secondary effects [2, 3].
However, as frequent monitoring of drug levels and
CMV viral load is not routine practice for cCMV
management in immunocompetent patients in most
centres, there is a lack of information regarding emer-
gence and sequelae of resistance mutations. To date, not
many cases have been described in the literature; the
first case was born prematurely with hydrops foetalis.
The infant died at 113 days of life, having failed to re-
spond to treatment. Although the information is limited,
resistance mutations seemed to be present very early on,
but the proportion of resistant strain increased over time
as detected by pyrosequencing [4]. The second case, re-
ported by Campanini et al. [5], was of a symptomatic
newborn diagnosed at birth with cCMV who developed
multidrug resistance, including to ganciclovir, with an
increase in symptoms. The third case was a preterm in-
fant with symptomatic cCMV infection who presented
with 5 mutations associated with ganciclovir resistance
after 120 days of treatment with (val)ganciclovir [6]. Un-
fortunately no virological information was available
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before that point. The fourth case was described by Choi
et al. [7], in a patient who developed (val)ganciclovir re-
sistance noted as an increment in viraemia with no asso-
ciated symptoms; the viraemia cleared after stopping the
treatment. This patient developed neutropenia while on
ganciclovir.
Case presentation
We report a 6 month-old female infant, first daughter of
a healthy, young couple. The pregnancy was followed up
for microcephaly detected by prenatal ultrasound. The
patient was born by caesarean section for pathological
cardiotocography following premature rupture of mem-
branes at 35 weeks; the birth weight was 2.06 kg (25th
centile), and the head circumference was 30 cm (9th
centile).
At birth, in addition to microcephaly, she was noted to
have petechial rash, hepatosplenomegaly and respiratory
distress requiring CPAP for the first 48 h of life. The
platelet count was 44 × 103/μL and ALT was 6 IU/L.
CMV was detected by PCR in blood and urine on day 3
of life with a CMV DNA level in blood of 3.6 × 105 cop-
ies/mL. Ophthalmology assessment on day 4 of life
showed normal retinae bilaterally, and audiology screen-
ing on day 5 showed left sensorineural hearing loss
(60 dB). The MRI showed periventricular and multiple
thalamostriate areas of calcification.
In view of the symptomatic manifestations of cCMV in-
fection, the patient was started on valganciclovir (16 mg/kg
twice daily, commercially available solution) on day 5 of life.
Of note she was on home oxygen during the first
months and developed apnoeic episodes from day 27 of
life and on one occasion required intubation and mech-
anical ventilation for less than 24 h following a respira-
tory arrest. There was absence of gag reflex, as a
probable manifestation of congenital CMV, and the child
was fed via nasogastric tube.
Her viral loads were measured periodically in blood as
well as her trough and peak ganciclovir levels (Fig. 1).
Initially there was a reduction in CMV viral load. Her
valganciclovir dose was increased according to her
weight gain and drug levels and there were no concerns
regarding compliance.
Clinically, she was making steady progress, specifically
in her weight gain and neurodevelopment, although
there were some inter-current episodes of respiratory
deterioration coincidental with flaring up of the petech-
ial rash with normal platelet counts.
After 4 months of treatment, an increase in viral load
was noted reaching a peak of 3.6 × 106 copies/mL, as
seen in the Fig. 1. Her valganciclovir had been maxi-
mised up to 140% the standard treatment dose because
of low drug levels and no signs of toxicity.
Blood was therefore sampled for viral nucleotide sequen-
cing analysis (Manchester Medical Microbiology Partner-
ship), which confirmed the presence of the A594V
mutation in the CMV UL97 gene conferring resistance to
ganciclovir. No mutations were detected in the UL54 gene,
inferring sensitivity to foscarnet and cidofovir. The retro-
spective analysis of a sample when the patient was 2 months
of age identified no known CMV resistance mutations.
Fig. 1 Timeline showing viral loads and ganciclovir (GC) levels measurements, as well as the determination of mutations
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Her full blood count, liver function tests and electro-
lytes remained within normal limits.
Valganciclovir was therefore stopped at 5 months of
age. In view of her steady improvement, no benefit was
felt in starting any of the other alternative drugs, such as
foscarnet or cidofovir, which are associated with signifi-
cant toxicity, have limited CNS penetration and require
intravenous administration. There were no signs of pri-
mary immunodeficiency, including a normal lymphocyte
subset panel, and her CMV level taken when stopping
treatment had decreased to 3.5 × 103 copies/mL. In
addition, her IgM and IgG, both negative at 4 months,
were found to be positive, with high avidity IgG. One
month after the end of treatment her viral load contin-
ued to decrease, with a level below 2 × 103 at 6 months
of age, and was undetectable at 9 months of age. At
2.5 years of life CMV was not unexpectedly still detected
in urine, but levels were too low for reliable mutation
analysis. In spite of her marked developmental delay she
was still making some steady progress. She can pull her-
self to stand, and sit unaided, but has no saving reflex
when she falls, and she can grasp and transfer toys. Vi-
sion is normal, she does not require hearing aids, and
she is vocalising, but uses no single words. She devel-
oped severe epilepsy at about 2 years of life..
Conclusions
To date, this is the fifth case of cCMV resistant to ganci-
clovir described in the literature while on treatment. The
pro-drug valganciclovir was used throughout treatment.
Her weight and drug levels were closely monitored, with
subsequent increments of the valganciclovir dose, aiming
for 0.5–1.0 mg/L and 7–9 mg/L for trough and peak
levels respectively. Of note, before emergence of the re-
sistant strain, the patient had a period of suboptimal
levels in spite of having her dose maximised. Although
poor adherence cannot be fully excluded, this observa-
tion may reflect individual variation in the pharmacokin-
etics of valganciclovir [8]. There were no signs of
malabsorption. Fortunately, she did not present any ad-
verse effect such as neutropenia, thrombocytopenia or
renal toxicity.
At the time CMV resistance was identified clinical
progress was steady despite the rise in viral load. Once
the resistant strain was detected, a decision was made to
stop her treatment. In subsequent follow up, she sero-
converted to IgG with high avidity and her viral load de-
clined, showing an effective immune response to control
the infection. We postulate that the rise in the viral load
due to the resistance resulted in an increased immune
stimulus to CMV, acting as a boost to immunity and,
subsequently, a fall in the viral load.
This case adds another example of cCMV and high-
lights the importance of frequent monitoring to detect
resistant strains, as well as adverse effects related to
treatment. As treatment for symptomatic cCMV has
been recommended with (val)ganciclovir (1), the emer-
gence of resistance mutations is a potential risk given
the combination of high viral loads, prolonged treat-
ment, and the potential for suboptimal drug levels even
with dose increments in newborns and infants [8–10].
This risk of resistance increases with longer durations of
treatment, which is of relevance given recent evidence
advocating a 6 month treatment course in light of
slightly improved outcome in terms of language and re-
ceptive communication [2, 3]. A risk of 5–10% for emer-
gence of resistance has been suggested with long term
ganciclovir therapy in transplant recipients [9]. Because
recommendations for 6 months treatment for cCMV are
new, surveillance to identify emerging resistance and op-
timisation of antiviral dosing accounting for weight-
changes and therapeutic drug monitoring are vital1.
Once weekly or fortnightly trough and peak levels (2 h
post dose) until stabilisation would be recommended.
Intervals could then be increased provided the dose is
increased weekly with weight gain. This could however,
be monitored remotely from home, or via the GP or
community service if needed. Finally, it is important to
remember that the risk of infection for cCMV can be de-
creased following simple hygiene measures such as hand
washing after nappy changes or wiping a child’s nose
[11–13]. Health care professionals should ensure that
pregnant woman are aware of the importance of these
measures.
Endnotes
1After the introduction of the recommendations of
(val)ganciclovir treatment for symptomatic congenital
CMV, surveillance with periodic viral loads and drug
monitoring are vital to identify emerging resistance and
optimise antiviral dosing in line with weight gain.
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